Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of HLX07 in advanced unresectable or metastatic esophageal squamous cell carcinoma
CTR20220274Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pimurutamab in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenosquamous carcinoma (ASC) (2 cohorts), sponsored by HyBioPharma. Primary endpoints: Progression-free survival and Objective response rate. Started Aug 2022; status: active.
02
Drugs
pimurutamab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenosquamous carcinoma (ASC)
Beyond the preview
Go deeper on CTR20220274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220274.